The global rheumatic disorders drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Rheumatic disorders are a wide range of conditions that are characterized by chronic pain, with some of the most common conditions being osteoarthritis (OA) and rheumatoid arthritis (RA), and it is estimated that about one in four adults in America is diagnosed with a rheumatic disorder. The rheumatic disorder therapy area is multi-disciplinary and encompasses conditions that affect joints, connective tissue, ligaments, tendons, cartilage, bone and muscle and which are characterized by chronic pain and a consequent reduction in function and motion. 

The majority of rheumatic disorders are treated using largely genericized pain management drugs. The incidence of many indications within the rheumatic disorders therapy area continues to rise and as the global population ages prevalence will increase which is a key driver of market growth. The market growth will also be driven by the entry of new products to the market, with two drug classes, in particular, driving the strong market growth.

The global rheumatic disorders drug market analysis includes some of the key market players such as AbbVie Inc, Amgen Inc., Johnson & Johnson Services Inc., Novartis International AG, among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships and collaborations, and mergers and acquisitions. For instance, in November 2021, Sandoz Egypt, in collaboration with the Egyptian Orthopedic Association (EOA), has announced the launch of a new non-steroidal anti-inflammatory drug (NSAID from Sandoz), etoricoxib, for the treatment of arthritis and chronic rheumatic disorders symptoms.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: AbbVie Inc, Amgen Inc., Johnson & Johnson Services Inc., Novartis International AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Rheumatic Disorders Drug Market Report Segmentation

By Route of Administration

• Oral

• Parenteral

By Drug Class

• Disease-modifying Anti-rheumatic Drugs (DMARDs)

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

• Corticosteroids

• Uric Acid Drugs

• Others

Global Rheumatic Disorders Drug Market by Region